Please login to the form below

Not currently logged in
Email:
Password:

neutropaenia

This page shows the latest neutropaenia news and features for those working in and with pharma, biotech and healthcare.

Neulasta rival from Teva cleared in EU

Neulasta rival from Teva cleared in EU

Lonquex offers competition to Amgen drug in neutropaenia. Teva Pharmaceutical has been given a green light by the European Commission (EC) for Lonquex, a rival to Amgen's blockbuster Neulasta. ... Lonquex (lipegfilgrastim) has been approved to reduce the

Latest news

  • Lonza ends biosimilars deal with Teva Lonza ends biosimilars deal with Teva

    Teva's current efforts in the area include tbo-filgrastim - a biosimilar version of Amgen's Neupogen, which is approved for use  to hasten recovery from instances of neutropaenia in certain

  • R&D news in brief

    ìThe drug appears to be well tolerated, with thrombocytopaenia and neutropaenia, being the main side effects that require careful monitoring.î.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics